scholarly journals Combined Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for the Treatment of Advanced Ovarian Cancer

10.5772/26816 ◽  
2012 ◽  
Author(s):  
Antonios-Apostolos K. ◽  
Nicolaos Courcoutsakis ◽  
Panos Prasopoulos
Keyword(s):  
Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Advanced Ovarian Cancer

Splenectomy in Cytoreductive Surgery for Advanced Ovarian Cancer and Subsequent Intraperitoneal Chemotherapy

2010 ◽  
Vol 26 (3) ◽  
pp. 179-182
Author(s):  
Alok C. Pant ◽  
Antonio Santillan ◽  
Teresa Diaz-Montes ◽  
Robert L. Giuntoli ◽  
Robert E. Bristow
Keyword(s):  
Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Advanced Ovarian Cancer

scholarly journals Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival with Acceptable Safety for Advanced Ovarian Cancer: A Clinical Study of 100 Patients

2021 ◽  
Vol 2021 ◽  
pp. 1-12
Author(s):  
Jue Zhang ◽  
Xin-bao Li ◽  
Zhong-he Ji ◽  
Ru Ma ◽  
Wen-pei Bai ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Surgical Treatment ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Peritoneal Cancer Index ◽  
Karnofsky Performance Status ◽  
Univariate Analysis ◽  
Advanced Ovarian Cancer ◽  
First Line

Background. The mainstay of treatment for advanced ovarian cancer is debulking surgery followed by chemotherapy that includes carboplatin and paclitaxel, but the prognosis is poor. This study is aimed at evaluating the efficacy and safety of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) as first-line surgical treatment in patients with advanced ovarian cancer (AOC). Methods. FIGO stage III/IV AOC patients underwent CRS+HIPEC as first-line surgical treatment at our center from December 2007 to January 2020. The primary endpoint was survival, and the secondary endpoint was safety. Results. Among 100 patients, the median Karnofsky performance status (KPS) score was 80 (50-100), median peritoneal cancer index (PCI) was 19 (1-39), median completeness of cytoreduction (CC) score was 1 (0-3), number of organ regions removed was 4 (3-9), number of peritoneal regions removed was 4 (1-9), and number of anastomoses was 1 (0-4). The median follow-up was 36.8 months; 75 (75.0%) patients were still alive, and 25 (25.0%) had died. The median overall survival (mOS) was 87.6 (95% CI: 72.1-103.0) months, and the 1-, 2-, 3-, 4-, and 5-year survival rates were 94.1%, 77.2%, 68.2%, 64.2%, and 64.2%, respectively. Univariate analysis showed that better mOS correlated with an age ≤, KPS ≥ 80 , ascites ≤ 1000  ml, PCI < 19 , and CC score 0-1. Multivariate Cox analysis showed that CC was an independent factor for OS; patients who underwent CRS with a CC score 0-1 had a mPFS of 67.8 (95% CI: 48.3-87.4) months. The perioperative serious adverse event and morbidity rates were 4.0% and 2.0%, respectively. Conclusions. CRS+HIPEC improves survival for AOC patients with acceptable safety at experienced high-volume centers. Stringent patient selection and complete CRS are key factors for better survival.

CYTOREDUCTIVE SURGERY IN THE TREATMENT OF ADVANCED OVARIAN CANCER: A COMPARATIVE ANALYSIS OF THE RESULTS

2019 ◽  
Vol 65 (1) ◽  
pp. 142-146
Author(s):  
Aleksey Shelekhov ◽  
Viktoriya Dvornichenko ◽  
Sergey Radostev ◽  
Rodion Rasulov ◽  
Dmitriy Morikov ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Advanced Ovarian Cancer ◽  
Operation Time ◽  
Cancer Center ◽  
Significant Difference ◽  
Disease Free

The first experience of cytoreductive surgery technology and intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) usage in the practice of Irkutsk Regional Cancer Center. All subjects were divided into 2 groups: the group of clinical comparison - the patients after suboptimal cytoreduction (53 persons), and the main group - the patients after optimal or complete debulking operation and hyperthermic intraperitoneal chemotherapy in some cases (32 persons). The subjects had ovarian cancer. The indispensable prerequisite of picking was confirmed carcinomatous peritoneal spread, resectable process, overall status. The primary analysis assay included time factors such as preoperation period, operation time, postoperative bed-days, in plus, complications and their character in postoperative period. In the article there are statistics of disease-free and overall survival in all groups and full consistent outline of the intraoperative hyperthermic chemotherapy method. The research has prospective character, observation continued. Expected results will be significant difference of disease-free and overall survival in the groups of interest.

Cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy in the treatment of advanced ovarian cancer

2010 ◽  
Vol 36 (10) ◽  
pp. 1030
Author(s):  
Claire de La Hosseraye ◽  
Reza Kianmanesh ◽  
Enrico Facchiano ◽  
Jean-Marc Sabate' ◽  
Benjamin Castel ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Intraperitoneal Chemotherapy ◽  
Cytoreductive Surgery ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Advanced Ovarian Cancer
Sign in / Sign up

Export Citation Format

Share Document